EBioMedicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2023-03-16 1e16a6dfm27(暂无匿称) 来自北京

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：免疫
经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！
2022，July 7， submitted

July 12， under review

July 18，Required Reviews Completed

July 19，under review

July 25，under review

July 27，Required Reviews Completed

Jul 31, Revise

Sep 07， Revision Submitted to the journal
Sep 07，With Editor
Sep 07，under review

Sep 18, 2022 Required Reviews Completed

Sep 29, 2022 Revise

Oct 29, 2022 Revision Submitted to Journal

Oct 30, 2022 With Editor

Nov 06, 2022 under review

Nov 07, 2022 Required Reviews Completed

Nov 08, 2022 编辑发邮件让修改参考文献格式

Nov 09, 2022 Accept

710 12 举报

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2021-08-23 惨兮兮的RA

审稿速度:2.0 | 投稿命中率:25.0
经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。

245 12 举报

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2019-11-05 Leoharlan

审稿速度:3.0 | 投稿命中率:25.0
经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。
编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！
之后有问题的朋友可以交流

482 10 举报

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2021-09-09 ms3211462863917894

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：转化医学;药理学
经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。

179 10 举报

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2022-01-30 1de49043m36(暂无匿称)

刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命

509 9 举报

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2022-10-20 y-y-y

审稿速度:2.0
偏重的研究方向：转化医学;临床转化
经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。

311 7 举报

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2020-09-24 亚*拉

审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0
偏重的研究方向：精神病学
经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。

257 7 举报

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2023-12-11 ms1000000959787142 来自天津

各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢

229 6 举报

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2019-05-11 haiyang0518

审稿速度:1.0 | 投稿命中率:25.0
经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，

305 6 举报

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=710, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=482, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=509, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=)]

2022-11-22 guolihuihelan_91618321

这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利

288 6 举报

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务